SCHEDULE: RA Capital Discloses 9.9% Stake in Rani Therapeutics

RA Capital Management and its affiliates have reported a 9.9% beneficial ownership stake in Rani Therapeutics Holdings, Inc., primarily through shares and warrants.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed a Schedule 13G for Rani Therapeutics Holdings, Inc.
• The Reporting Persons collectively beneficially own 9,882,477 shares of Rani Therapeutics' Class A Common Stock.
• This represents 9.9% of the Class A Common Stock outstanding, rounded down from 9.99% due to EDGAR system limitations.
• The ownership includes 8,500,000 directly held Class A common shares by RA Capital Healthcare Fund, L.P.
• Additionally, the Fund holds pre-funded warrants exercisable for up to 16,500,000 shares and common warrants exercisable for up to 25,000,000 shares.
• Warrants contain "Beneficial Ownership Blockers" preventing exercise if it would result in ownership exceeding 9.99% of outstanding Class A common stock.
• Common Warrants require stockholder approval for exercisability, per Nasdaq rules.
• The beneficial ownership percentage is calculated based on 97,541,221 shares outstanding as of October 23, 2025, plus 1,382,477 shares issuable from warrants.
• The Reporting Persons disclaim "group" status and state the securities were not acquired to change or influence control, except for potential nominations under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a reputable healthcare investor like RA Capital is generally a positive signal for the company, indicating investor confidence. However, the limitations on warrant exercise and the need for stockholder approval introduce some minor uncertainties.

Positives

• A significant institutional investor, RA Capital Management, holds a substantial stake (9.9%) in Rani Therapeutics, indicating confidence in the company.
• The investment includes a mix of direct shares and warrants, providing potential for increased future ownership.

Negatives

• The "Beneficial Ownership Blockers" in the warrants limit the immediate upside potential for RA Capital to increase its stake beyond 9.99% without further action or changes.
• The exercisability of Common Warrants is contingent on stockholder approval, introducing a potential delay or uncertainty.

Risks

• The "Beneficial Ownership Blockers" in the warrants prevent the Reporting Persons from exercising warrants if it would result in ownership exceeding 9.99% of the Class A common stock outstanding, potentially limiting their influence or ability to increase their stake.
• The Common Warrants are not exercisable until the effective date of stockholder approval, which could be delayed or not granted, impacting the full realization of the warrant's value.

Future Outlook

NA

Industry Context

This filing indicates continued institutional investor interest in the biotechnology or pharmaceutical sector, specifically in companies like Rani Therapeutics. Large stakes by specialized healthcare funds like RA Capital often signal a belief in the long-term potential of the company's technology or pipeline.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake could be viewed positively, potentially increasing investor confidence. The limitations on warrant exercise and the need for stockholder approval for common warrants are relevant to existing shareholders.
• Company (Rani Therapeutics): The potential future exercise of warrants could provide capital, but the current blockers and approval requirements mean this capital is not immediately accessible from all warrants.

Next Steps

• Rani Therapeutics' stockholders will need to approve the exercisability of the Common Warrants.

Key Dates

Recommendation

The filing indicates a significant institutional investor's confidence in Rani Therapeutics through a substantial ownership stake. While this is generally positive, the existing 'Beneficial Ownership Blockers' and the requirement for stockholder approval for common warrants introduce limitations and uncertainties. Investors should hold and monitor the company's progress and the outcome of the warrant exercisability vote before making further investment decisions.

Keywords

Rani Therapeutics, RA Capital Management, Schedule 13G, Beneficial Ownership, Class A Common Stock, Warrants, Biotechnology, Healthcare Investment, Institutional Investor, SEC Filing